A Case of Anti-TNFα Therapies Induced Lupus Panniculitis Successfully Improved With a JAK Inhibitor (Baricitinib)

被引：0
|
作者：
Grechin, Cristina [1 ]
Doheny, Jane [2 ]
Pilson, Keith [2 ]
Howard, Donough [3 ]
Roche, Muireann [1 ]
机构：
[1] Beaumont Hosp, Dermatol Dept, Dublin, Ireland
[2] Beaumont Hosp, Histopathol Dept, Dublin, Ireland
[3] Beaumont Hosp, Rheumatol Dept, Dublin, Ireland
来源：
JEADV CLINICAL PRACTICE | 2025年
关键词：
anti-TNF-alpha therapies; JAK inhibitor; lupus panniculitis; rheumatoid arthritis; ADALIMUMAB;
D O I：
10.1002/jvc2.626
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Lupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus (1%-3% of CLE). There are two case reports to date in the literature of LEP potentially triggered by anti-TNF-alpha therapies. Clinically, it is characterised by tender, erythematous subcutaneous indurated nodules or plaques on fatty body areas. It can occur frequently alone or in combination with systemic erythematous lupus or discoid lupus. The pathogenic mechanism of anti-TNF-alpha therapies induced lupus panniculitis is not well understood. Our case report and literature review highlight that anti-TNF-alpha therapies can induce lupus panniculitis, especially in the rheumatoid arthritis cohort of patients.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Characterization of Patients with Infliximab-induced Lupus Erythematosus and Outcomes After Retreatment with a Second Anti-TNF Agent
    Subramanian, Sreedhar
    Yajnik, Vijay
    Sands, Bruce E.
    Cullen, Garret
    Korzenik, Joshua R.
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) : 99 - 104
  • [32] Association between anti-TNFα drug levels and drug-induced lupus in patients with Inflammatory Bowel Disease
    Munoz-Villafranca, C.
    Irabien, M.
    Hernandez-Aretxabaleta, N.
    Arreba, P.
    Ortiz de Zarate, J.
    Garcia-Gomez, C.
    Aresti, U.
    Bilbao, A.
    Irigoyen, M.
    Garcia-Vivar, M. L.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S281 - S282
  • [33] IN PREVIOUSLY BIOLOGIC-NAIVE RHEUMATIC PATIENTS WITH DRUG INDUCED LUPUS SECONDARY TO A FIRST ANTI-TNF THERAPY, IS IT SAFE TO SWITCH TO A SECOND ANTI-TNF-α AGENT?
    Martins, A.
    Santos Oliveira, D.
    Martins, F. R.
    Oliveira Pinheiro, F.
    Rato, M.
    Fonseca, D.
    Garcia, S.
    Fernandes, B. M.
    Pimenta, S.
    Bernardes, M.
    Costa, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1266 - 1266
  • [34] Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature
    Ora Shovman
    Shalev Tamar
    Howard Amital
    Abdulla Watad
    Yehuda Shoenfeld
    Clinical Rheumatology, 2018, 37 : 563 - 568
  • [35] Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature
    Shovman, Ora
    Tamar, Shalev
    Amital, Howard
    Watad, Abdulla
    Shoenfeld, Yehuda
    CLINICAL RHEUMATOLOGY, 2018, 37 (02) : 563 - 568
  • [36] Anti-TNF-α-induced lupus syndrome Two case reports and review of current literature
    Sieiro Santos, Cristiana
    alvarez Castro, Carolina
    Moriano Morales, Clara
    Diez alvarez, Elvira
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (05): : 481 - 486
  • [37] Etanercept-induced colitis and watery diarrhoea in an elderly patient:: a case report -: Anti-TNF agents are not equal?
    Nergard, C. S.
    Johansen, M.
    DRUG SAFETY, 2006, 29 (10) : 946 - 946
  • [38] Improved quality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNFα therapies
    Keystone, E. C.
    Burmester, G. R.
    Furie, R. A.
    Loveless, J. E.
    Emery, P.
    Isaacs, J.
    Jubb, R.
    Dawes, P.
    Cravets, M. W.
    Magrini, F.
    RHEUMATOLOGY, 2006, 45 : I46 - I47
  • [39] Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey
    Lesage, Candice
    Longvert, Christine
    Prey, Sorilla
    Maanaoui, Sarah
    Dreno, Brigitte
    Machet, Laurent
    Zehou, Ouidad
    Kramkimel, Nora
    Jeudy, Geraldine
    Skowron, Francois
    Aubin, Francois
    Visseaux, Laetitia
    Mansard, Sandrine
    Dereure, Olivier
    Lesage, Francois-Xavier
    Guillot, Bernard
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (05) : 175 - 179
  • [40] Safety and Efficacy of ABT-494, a Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
    Kremer, Joel M.
    Keystone, Edward C.
    Emery, Paul
    Camp, Heidi S.
    Friedman, Alan
    Wang, Li
    Othman, Ahmed A.
    Khan, Nasser
    Jungerwirth, Steven
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345